Altimmune

Altimmune is a clinical-stage biopharmaceutical company pioneering novel peptide-based therapeutics for obesity and metabolic diseases. Its lead asset, pemvidutide, is a GLP-1/glucagon dual agonist demonstrating competitive weight loss and liver fat reduction in mid-stage trials. The company leverages a proprietary platform to design targeted, multi-agonist peptides with the potential for differentiated efficacy and safety profiles.